DOCSLIB.ORG

United States Patent (19) 11, 3,931, 195 Dykstra Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11, 3,931, 195 Dykstra Et Al United States Patent (19) 11, 3,931, 195 Dykstra et al. (45) Jan. 6, 1976 (54) SUBSTITUTED PIPERIDINES Krapcho et al., J. Med. Chem. Vol. 7, pp. 376 to 377, 75 Inventors: Stanley J. Dykstra; Joseph L. (1964). Minielli, both of Evansville, Ind. Krapcho et al., J. Med. Chem. Vol. 9, pp. 809 to 812, (1966). 73) Assignee: Mead Johnson & Company, Krapcho et al., J. Med. Chem. Vol. 12, pp. 164 to Evansville, Ind. 166, (1969). (22 Filed: July 31, 1973 Phillips, J. Am. Chem. Soc. Vol. 72, pp. 1850 to 1852, (21) Appl. No. 384,341 (1950). Related U.S. Application Data Primary Examiner-John D. Randolph 63 Continuation-in-part of Ser. No. 20,754, March 3, Attorney, Agent, or Firm-R. H. Uloth; R. E. 1971, abandoned. Carnahan 52 U.S. Cl.......... 260/293.58; 424/267; 260/240 J; 260/293.73; 260/293.57; 260/293.58; 57 ABSTRACT 260/293.59; 260/293.77 The compounds are of the heterocyclic class of 2 (5ll Int. Cl’........................................ C07D 211/08 phenethylpiperidines having an amido substituent in (58) Field of Search..... 260/293.77, 293.57, 293.58, the ortho position of the phenethyl moiety. Substitu 260/293.59, 240 J, 293.73 ents in the ortho position include formamido, ben Zamido, cinnamamido, 2-thiophenecarboxamido, al (56) References Cited kanesulfonamido and alkanoylamido. They are useful as antiarrhythmic and/or antiserotonin agents. The UNITED STATES PATENTS novel compounds are prepared by reaction of appro 2,686,784 81954 Finkelstein et al.............. 260.1293.7 priately substituted o-aminophenethylpiperidines and 2,780,577 2/1957 Phillips et al.................... 260/293.7 the carbonyl or sulfonyl halides or anhydrides. Typical 3, 192.23 6/1965 Krapcho............................. 260/253 embodiments of this invention are 4-methoxy-2'-2- OTHER PUBLICATIONS (1-methyl-2-piperidyl)ethylbenzanilide and 2'-2-(l- Lawson, J. Pharm. Exp. Therap. 160, pp. 22 to 31, methyl-2-piperidyl)ethyl)cinnamanilide. (1968). Krapcho et al., J. Med. Chem. Vol. 6, p. 219, (1963). 28 Claims, No Drawings 3,931, 195 1 sUBSTITUTED PIPERIDINEs. CROSS-REFERENCE TO RELATED APPLICATIONS 5 This application is a continuation-in-part of co-pend ing U.S. application Ser. No. 120,754 filed. Mar. 3, 1971, now abandoned. BACKGROUND OF THE INVENTION 10 The present invention is concerned with certain het erocyclic organic compounds which can be referred to as substituted piperidines and acid addition salts thereof. In particular, this invention relates to physio logically active novel piperidine compounds which are 15 particularly effective as antiarrhythmic and antiseroto Formula XII nin agents. It is also concerned with chemical interme diates useful in the preparation of the piperidine com pounds. Other features of the invention are pharma ceutical compositions containing the piperidines as 20 active ingredients and a therapeutic process for pro ducing antiserotonin and antiarrhythmic effects in mammals by administration of them. Agents which antagonize serotonin are of interest in experimental biology and in treatment of various physi 25 ological disorders such as migraine headache, seroto nin producing tumors, toxemia in pregnancy, habitual The substances of Formula I and Formula XI are new abortion and management of various inflammatory and compositions of matter possessing valuable pharmaco allergic reactions. Methysergide and lysergide are well logical properties which render them useful as syn known antiserotonin agents. Other serotonin antago 30 thetic medicinals. In particular, the substituted piperi nists which have been reported in the prior art litera dines of Formula I and Formula XII exhibit utility as ture on the subject are 2'-(3-dimethylaminopropylthi antiserotonin and/or antiarrhythmic agents in standard o)cinnamanilide and related compounds disclosed by pharmacological tests in mammals. This invention also Krapcho, et al., J. Med. Chem., 6, 219 (1963); 7, 376 is concerned with the production of the compounds of (1964); 9,809 (1966); and 12, 164 (1969); and U.S. 35 Formulas I and XII from novel chemical intermediates, Pat. No. 3, 192,213. pharmaceutical compositions containing them and a A number of structurally unrelated chemical sub therapeutic process for producing an antiserotonin stances have been employed in the treatment of cardiac effect in mammals comprising the administration of arrhythmia; refer to A. Burger, Medicinal Chemistry, such compounds thereto. Another feature of this inven 3rd Edition, pages 1082-1085 (Wiley). One of the 40 tion is a therapeutic process for producing an antiar most important drugs in clinical treatment of disorders rhythmic effect in mammals by administration of com of cardiac rhythm is quinidine. Another chemical agent pounds of Formula I wherein R is R substituted cin which has been used as an antiarrhythmic is the local namoyl as depicted by Formula Ia or R." substituted anesthetic procaine amide. Still other antiarrhythmic benzoyl as depicted by Formula Ib. agents are lidocaine, and diphenylhydantoin. None of 45 Still another feature of this invention provides novel these compounds are structurally related to the piperi o-aminophenethylpiperidines of Formula II which are dines of the present invention. useful as chemical intermediates in the production of compounds of Formula I. SUMMARY OF THE INVENTION This invention relates to a series of substituted piperi 50 dines characterized by Formula I and Formula XII and non-toxic pharmaceutically acceptable acid addition salts thereof. 55 60 65 Formula I Formula I 3,931, 195 3 - 4. In the compounds characterized by the above general The symbol R represents hydrogen or lower alkyl Formulas I and II, the R substituent stands for hydro and R' is seleeted from the group consisting of hydro gen or lower alkyl. The substituent R represents hy gen, halogen, trifluoromethyl, amino, dimethylamino, drogen, lower alkoxy or methylenedioxy attached in hydroxy, acetoxy, carboxy, alkylthio of from 1 to 4 the benzenoid 4,5-position. R' stands for hydrogen or a 5 carbon atoms inclusive, alkyl of from 1 to 4 carbon lower alkyl substituent. Substituent R represents hy atoms inclusive, lower alkoxy of from 1 to 4 carbon drogen, lower alkyl, or a dialkylcarboxamido substitu atoms inclusive, and wherein when R is hydrogen or ent wherein the dialkyl groups are lower alkyl. alkoxy the phenyl ring can have up to 2 additional Substituent R represents radicals selected from the alkoxy substituents of, from 1 to 4 carbon atoms inclu group comprised of lower alkanoyl of from 1 to 4 car O SWC. bon atoms inclusive, lower alkanesulfonyl of from 1 to In the compounds characterized by Formula XII, the 4 carbon atoms inclusive, symbol R represents' hydrogen or lower alkyl. The symbol. R9 represents a radical selected from the group consisting of cinnamoyl or . 15 p O 20 wherein R is lower alkoxy. The symbol A represents a "isonipecotoyl" "pyridylcarbonyl" divalent radical selected from the group consisting of -CH,-, --GH-, --GH-, 25 . .CH, bH . -HCH- -CHCH-, -CHCHCH--, bh, &H, ÖH - - - - 30 and -(CH2)3-. It is to be understood that the term “lower alkyl" and “lower alkoxy” as used herein refers to carbon chains --C- - which include both straight and branched chain carbon . ) radicals of from 1 to 4 carbon atoms inclusive. Illustra tive of these radicals are carbon chains which can be methyl, ethyl, propyl, isopropyl, 1-butyl, 1-methylpro "3-furylcarbonyl". pyl, 2-methylpropyl and tert-butyl. Compounds which are particularly preferred for their strong antiserotonin activity are compounds of For - 40. mula Ia. - . 45 9 50. CuC-C- , CHC-C- "phenylpropioloyl" "cinnamoyl" 55 Formula Ia 60 O wherein R', R°, R, R and R have the meanings here inabove given for Formula I. Representative of these C compounds is the individually preferred compound R” 2'-(2-(1-methyl-2-piperidyl)ethyl)cinnamanilide. 65. Compounds of the present invention which are par ticularly preferred for their strong antiarrhythmic ac "benzoyl" tivity are those of Formula Ib. 3,931,195 S 6 Zenesulfonic, para-toluenesulfonic, acetic, lactic, suc - R' cinic, maleic, mucic, tartaric, citric, gluconic, benzoic, cinnamic, isethionic and related acids. R N The compounds characterized by Formula I and For mula XII exhibit valuable antiarrhythmic activity in mammals. These antiarrhytmic effects are illustratively Ne-C demonstrated in standard in vitro and in vivo pharma 1. R7 cological tests. R In the dog, for example, electrically or aconitine 10 induced arrhythmia is prevented by oral or parenteral administration of the piperidines of Formula I accord ing to the following in vivo test. The chest of an anesthetized dog is opened in the midline and the right and left atrial appendages ex Formula. Ib 15 posed through small slits in the pericardium. Bypolar recording electrodes are affixed to the atrial surfaces and 4 x 4 mm. piece of clean cloth is fixed to the sur face of the right auricular appendage. Control record ings are made of various heart functions including fem 20 oral arterial blood pressure and right and left atrial electrograms. Atrial arrhythmia is then induced by wherein R, R, R, R, and R7 have the meanings here placing 3-5 drops of a solution of aconitine on the cloth inabove given for Formula I. Representative of these which is fixed to the right atrium. An irregular, rapid compounds are the individually preferred compounds atrial rate is produced within one minute. Throughout 4-methoxy-2'-(2-(1-methyl-2-piperidyl)ethyl)benzani 25 the experiment, fresh aconitine is (2-3 drops) placed lide, and 2'-(2-(1-methyl-2-piperidyl)ethyl-3,4,5- on the cloth at 10 minute intervals. The test compound trimethoxybenzanilide. is administered intravenously five minutes after the A still further group of preferred compounds are initial establishment of the arrhythmia and infusion those characterized by Formula Ib wherein R, R, and continued at a slow rate until an effective dose which Rare hydrogen, R is methyl and R is hydrogen or 30 re-establishes normal rhythm of the heart is obtained.
Load more

Recommended publications
  • United States Patent [19] [11] 15 Re. 30,811 Dykstra Et A1
    United States Patent [19] [11] 15 Re. 30,811 Dykstra et a1. [45] Reissued Dec. 1, 1981 [54] SUBSTITUTED PIPERIDINES 2,780,577 2/1957 Phillips et a]. .................. .. 424/267 THERAPEUTIC PROCESS AND 3,192,213 1/1965 Krapcho . .. 260/253 COMPOSITIONS 3,789,072 1/1974 Bernstein ...... .. 260/557 D 3,931,195 1/1976 Dykstra et a1. .............. .. 260/293.58 [75] Inventors: Stanley J. Dykstra; Joseph L. OTHER PUBLICATIONS Minielli, both of Evansville, Ind. 73 A. - ._ Mead J hnson 81 C a Lawson, J. Pharm. Ex p . Thera p ., 160, pp . 21-31 (1968). [ 1 ‘Slgnee Evansv?le in mm’ ‘W’ Krapcho et al., J. Med. Chem, 6, p. 219 (1963). ' Krapcho et al., J. Med. Chem, 7, pp. 376-377 (1964). [2!] Appl- NW 98.008 Krapcho et 31., .1. Med. Chem, 9, pp. 809-812 (1966). [22] Filed. No“ 28, 1979 Krapcho et al., J. Med. Chem, 12, pp. 164-166 (1969). Phillips, J. Am. Chem. Soc., 72, pp. 1850-1852 (1950). Related US. Patent Documents Primary Examiner—Stanley J. Friedman Reissue of. Attorney, Agent, or Firm-Robert H. Uloth; Robert E. [64] Patent NO.I 4,064,254 Camha" Issued: Dec. 20, 1977 [57] ABSTRACT F531:A 1. N 0 .: 0cL734,583 21 1976 The compounds are of the heterocycltc, class of 2 v _ ’ phenethylpiperidines having an amido substituent in the U-5- APPl1cat1°I151 ortho position of the phenethyl moiety. Substituents in 160] Dlvisio" 0151?’ NO- 620-207’ Ocl- 3» 19751 Pa" N°~ the ortho position include formamido, benzamido, cin 4‘00Oé143' wh‘ch '5 agd‘wls‘gn 025:", No- 384'34l' Jul" namamido, 2-thiophenecarboxamido, alkanesul 31' 1.
    [Show full text]
  • Derivatives of Carboxylic Acid
    Derivatives of Carboxylic Acid acid chloride carboxylate nitrile amide acid anhydride ester Nomenclature of Acid Halides IUPAC: alkanoic acid → alkanoyl halide Common: alkanic acid → alkanyl halide I: 3-aminopropanoyl chloride I: 4-nitropentanoyl chloride c: b-aminopropionyl chloride c: g-nitrovaleryl chloride I: hexanedioyl chloride c: adipoyl chloride Rings: (IUPAC only): ringcarbonyl halide I: benzenecarbonyl bromide I: 3-cylcopentenecarbonyl chloride c: benzoyl bromide Nomenclature of Acid Anhydrides Acid anhydrides are prepared by dehydrating carboxylic acids acetic anhydride ethanoic acid ethanoic anhydride I: benzenecarboxylic anhydride I: butanedioic acid I: butanedioic anhydride c: benzoic andhydride c: succinic acid c: succinic anhydride Some unsymmetrical anhydrides I: ethanoic methanoic I: benzoic methanoic anhydride anhydride I: cis-butenedioic c: benzoic formic anhydride anhydride c: acetic formic anhydride Nomenclature of Esters Esters occur when carboxylic acids react with alcohols I: phenyl methanoate I: t-butyl benzenecarboxylate I: methyl ethanoate c: phenyl formate c: methyl acetate c: t-butyl benzoate I: isobutyl I: cyclobutyl 2- I: dimethyl ethanedioate cyclobutanecarboxylate methylpropanoate c: cyclobutyl a- c: dimethyl oxalate c: none methylpropionate Cyclic Esters Reaction of -OH and -COOH on same molecule produces a cyclic ester, lactone. To name, add word lactone to the IUPAC acid name or replace the -ic acid of common name with -olactone. 4-hydroxy-2-methylpentanoic acid lactone -methyl- -valerolactone Amides Product of the reaction of a carboxylic acid and ammonia or an amine. Not basic because the lone pair on nitrogen is delocalized by resonance. Classes of Amides 1 amide has one C-N bond (two N-H). 2 amide or N-substituted amide has two C-N bonds (one N-H).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0022773 A1 Bruncko Et Al
    US 2010.0022773A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0022773 A1 Bruncko et al. (43) Pub. Date: Jan. 28, 2010 (54) APOPTOSIS PROMOTERS (22) Filed: Feb. 23, 2009 (76) Inventors: Milan Bruncko, Green Oaks, IL Related U.S. Application Data (US); Hong Ding, Gurnee, IL (US); (63) Continuation of application No. 1 1/127,940, filed on Steven Elmore, Gurnee, IL (US); May 12, 2005, which is a continuation-in-part of appli Aaron Kunzer, Schaumburg, IL cation No. 10/988,388, filed on Nov. 12, 2004, now (US); Christopher L. Lynch, abandoned. Trevor, WI (US); William McClellan, Waukegan, IL (US); (60) Provisional application No. 60/519,695, filed on Nov. Cheol-Min Park, Gurnee, IL (US); 13, 2003. Andrew Petros, Mundelein, IL (US); Xiaohong Song, Grayslake, Publication Classification IL (US); Noah Tu, Gurnee, IL (US); (51) Int. C. Xilu Wang, Oakwood, IL (US); C07D 24I/04 (2006.01) Michael Wendt, Vernon Hills, IL (US) (52) U.S. Cl. ........................................................ 544/392 Correspondence Address: (57) ABSTRACT PAUL. D. YASGER Disclosed are compounds which inhibit the activity of anti ABBOTT LABORATORIES apoptotic protein family members, compositions containing 100 ABBOTT PARK ROAD, DEPT. 377/AP6A the compounds and uses of the compounds for preparing ABBOTT PARK, IL 60064-6008 (US) medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein (21) Appl. No.: 12/390,945 family member. US 2010/0022773 A1 Jan. 28, 2010 APOPTOSIS PROMOTERS or N(CH)SO.N(CH) R', and the remainder are indepen dently selected H, F, Cl, Br, I, CF, C(O)OH, C(O)NH2 or 0001.
    [Show full text]
  • Accepted Version
    Citation for published version: Chapman, R, Lawrence, R, Williams, J & Bull, S 2017, 'Formyloxyacetoxyphenylmethane as an N-Formylating Reagent for Amines, Amino Acids, and Peptides', pp. 4908-4911. https://doi.org/10.1021/acs.orglett.7b02382 DOI: 10.1021/acs.orglett.7b02382 Publication date: 2017 Document Version Peer reviewed version Link to publication University of Bath Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 Formyloxyacetoxyphenylmethane as an N-Formylating Reagent for Amines, Amino Acids and Peptides Robert. S. L. Chapman,‡ Ruth Lawrence,‡ Jonathan M. J. Williams and Steven. D. Bull* Department of Chemistry, University of Bath, Bath, BA2 7AY, UK. ABSTRACT: Formyloxyacetoxyphenylmethane is a stable, water-tolerant, N-formylating reagent for primary and second- ary amines that can be used under solvent-free conditions at room temperature to prepare a range of N-formamides, N- formyl-anilines, N-formyl--amino-acids, N-formyl-peptides and an isocyanide. N-Formylation reactions of primary and secondary amines are as a catalyst free N-formylating reagent for -amino acids and important transformations in organic chemistry, because they peptides in aqueous based solvent systems.
    [Show full text]
  • WO 2013/057196 Al 25 April 2013 (25.04.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/057196 Al 25 April 2013 (25.04.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 501/36 (2006.01) A61P 31/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/546 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2012/070664 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 18 October 2012 (18.10.2012) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 11185954.2 20 October 201 1 (20. 10.201 1) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: DSM SINOCHEM PHARMACEUTICALS GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, NETHERLANDS B.V.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,973,161 B2 WAFS E.W. E. W (US); (52) U.S. C...54
    US007973161B2 (12) United States Patent (10) Patent No.: US 7,973,161 B2 Bruncko et al. (45) Date of Patent: *Jul. 5, 2011 (54) APOPTOSIS PROMOTERS (60) Provisional application No. 60/519,695, filed on Nov. 13, 2003. (75) Inventors: Milan Bruncko, Green Oaks, IL (US); Hong Ding, Gurnee, IL (US); Steven (51) Int. Cl. Elmore, Northbrook, IL (US); Aaron C07D 24I/02 (2006.01) Kunzer, Arlington Heights, IL (US); C07D 403/02 (2006.01) WAFS E.W. E. w (US); (52) U.S. C. ................................ 544/393; 54.4/121 (US);an Cheol-Min cellan, Park, waukegan, Singapore (SG); (58) Field of Classification Search ........................ None Andrew Petros, Mundelein, IL (US); See application file for complete search history. Xiaohong Song, Grayslake, IL (US); (56) References Cited Xilu Wang, Grayslake, IL (US); Noah Tu, Gurnee, IL (US); Michael Wendt, U.S. PATENT DOCUMENTS Vernon Hills, IL (US); Alexander 5,138,069 A 8, 1992 Carini et al. Shoemaker, Green Oaks, IL (US); 6,410,584 B1 6/2002 Pamukcu et al. Michael Mitten, Beach Park, IL (US) 6,720,338 B2 4/2004 Augeri et al. (73) Assignee: Abbott Laboratories, Abbott Park, IL (Continued) (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this NZ 230 136 12/1991 patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 1010 days. This patent is Subject to a terminal dis- OTHER PUBLICATIONS claimer. Thomas H. Corbett, et al., “Discovery and Preclinical Antitumor Efficacy Evaluations of LY32262 and LY33169. Investigational (21) Appl. No.: 11/600,445 New Drugs, Feb.
    [Show full text]
  • Sgc Stimulators Sgc-Stimulatoren Stimulateurs De Sgc
    (19) TZZ ¥_T (11) EP 2 637 659 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/427 (2006.01) A61K 31/4439 (2006.01) 18.05.2016 Bulletin 2016/20 A61K 31/444 (2006.01) A61K 31/497 (2006.01) A61K 31/506 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 11784873.9 C07D 401/14 C07D 403/04 C07D 407/14 (2006.01) C07D 413/14 (2006.01) C07D 417/04 (2006.01) C07D 417/14 (2006.01) (22) Date of filing: 02.11.2011 A61P 7/02 (2006.01) A61P 9/08 (2006.01) (86) International application number: PCT/US2011/058902 (87) International publication number: WO 2012/064559 (18.05.2012 Gazette 2012/20) (54) SGC STIMULATORS SGC-STIMULATOREN STIMULATEURS DE SGC (84) Designated Contracting States: • PERL, Nicholas, Robert AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Brookline GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO MA 02446 (US) PL PT RO RS SE SI SK SM TR • ROHDE, Jason Designated Extension States: Emeryville BA ME CA 94608 (US) (30) Priority: 09.11.2010 US 411730 P (74) Representative: Mullen, Lee Bryan et al 13.10.2011 US 201161546707 P Elkington and Fife LLP Thavies Inn House (43) Date of publication of application: 3-4 Holborn Circus 18.09.2013 Bulletin 2013/38 London EC1N 2HA (GB) (73) Proprietor: Ironwood Pharmaceuticals, Inc. (56) References cited: Cambridge, MA 02142 (US) EP-A1- 0 908 456 WO-A1-00/06568 WO-A1-93/11433 (72) Inventors: • KIM, Charles • SERGIEVSKII A V ET AL: "Reactivity of Cambridge 3,5-bis-(4-amino-1,2,5-oxadiazol-3-yl)-1,2 ,4-triaz MA 02139 (US) ole", RUSSIAN JOURNAL OF ORGANIC • NAKAI, Takashi CHEMISTRY, NAUKA/INTERPERIODICA, MO, Newton vol.
    [Show full text]
  • Synthesis of N-Formylation of Amines Using Various Ion Exchanged Forms of Zeolite-A As Catalysts
    Pharmacy & Pharmacology International Journal Research Article Open Access Synthesis of n-formylation of amines using various ion exchanged forms of zeolite-a as catalysts Abstract Volume 5 Issue 4 - 2017 A simple, convenient and new efficient procedure was utilized for the synthesis of Sami Ullah Bhat, Rawoof Ahmad Naikoo, N-Formylation of amines using Zeolite A as a heterogeneous solid acid catalyst. The main advantage of this protocol is less reaction time, high percentage yield, cleaner Radha Tomar, Rayees Ahmad Bhat, Manzoor and easy work up. The synthesized zeolites were characterized by various techniques Ahmad Malla, Javeed Ahmad Ganie, Neeraj Viz, Fourier-transform infrared spectroscopy(FTIR), X-ray diffraction(XRD) and Kumar, Kautily Rao Tiwari Scanning electron microscopy(SEM). The synthesized products were characterized by School of Studies in Chemistry, Jiwaji University, India HNMR and Fourier-transform infrared spectroscopy(FTIR) techniques. Furthermore the catalyst can be recovered conveniently and reused efficiently. Correspondence: Sami Ullah Bhat, School of Studies in Chemistry, Jiwaji University, Gwalior, India, Keywords: n-formylation, zeolite a, amines, less reaction time Email: [email protected] Received: July 25, 2017 | Published: September 12, 2017 Introduction was added and mixed gently in capped polypropylene bottle up to its clearance, thick gel was formed quickly after pouring silicate solution Formamides represent an important class of intermediates in into aluminate solution and polypropylene bottle was kept for 4h in various organic syntheses. They have been used in the synthesis oven at 99oC. The required mixture was washed by distilled water and of some pharmaceutically important compounds such as centrifuged up to PH ≤9 and dried at 100oC .The sample was ground 1 2 Fluoroquinolones, 1, 2 dihydro quinolones and Nitrogen based into powder and calcined at 500 oC for 4h in order to remove water 3 heterocyclic compounds.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,181.237 B2 Grote (45) Date of Patent: Nov
    US009181237B2 (12) United States Patent (10) Patent No.: US 9,181.237 B2 Grote (45) Date of Patent: Nov. 10, 2015 (54) SUBSTITUTED BERBINES AND THEIR OTHER PUBLICATIONS SYNTHESIS Jiaranaikulwanitch, J. et al.: Triazolyl tryptoline derivatives as beta (71) Applicant: MALLINCKRODT LLC, Hazelwood, Secretase inhibitors. Biorg. & medicinal Chem. letters, vol. 20, pp. MO (US) 6572-6576, 2010.* Kobayashi, J. et al.: Theoneberine; The first brominated (72) Inventor: Christopher W. Grote, Webster Groves, benzyltetrahydroberberine alkaloid from the Okinawan marine MO (US) sponge TheOnella sp., vol. 57, pp. 6680-6682, 1992.* Rastrelli, L. et al.: New Protopine and (73) Assignee: Mallinckrodt LLC, Hazelwood, MI benzyltetrahydroprotoberberine alkaloids from Aristolochia (US) constricta and their activity on isolated guinea-pig ileum.J. of Natu ral Prod., vol. 60, pp. 1065-1069, 1997.* (*) Notice: Subject to any disclaimer, the term of this Grycova et al., Quaternary protoberberine alkaloids, Phytochem. patent is extended or adjusted under 35 2007, 68(2): 150-175. U.S.C. 154(b) by 0 days. Mali et al., Novel syntheses of 1-substituted-7,8-dialkoxyisochro man-3-ones and 8-substituted.-2,3,9,10-tetramethoxyberbines, Tetra (21) Appl. No.: 14/504,906 hedron (1986), 42(7), 2075-82. Memetzidis, et al., Synthesis of Aromatic Chloroberbines, Hetero (22) Filed: Oct. 2, 2014 cycles (1990), 31(2), 341-51. Memetzidis, et al., Structure-affinity relationships of berbines or (65) Prior Publication Data 5,6,13,13a-tetrahydro-8H-dibenzoa, gduinolizines at O-adrenocep tors, Eur, J. Med. Chem., 1991, 26: 605-611. US 2015/OO99772 A1 Apr. 9, 2015 Nagubandietal. The mechanism of the Bischler-Napierski reaction, J.
    [Show full text]
  • The Atmospheric Oxidation of Ethyl Formate and Ethyl Acetate Over a Range of Temperatures and Oxygen Partial Pressures John J
    The Atmospheric Oxidation of Ethyl Formate and Ethyl Acetate over a Range of Temperatures and Oxygen Partial Pressures John J. Orlando and Geoffrey S. Tyndall, Atmospheric Chemistry Division, Earth and Sun Systems Laboratory, National Center for Atmospheric Research, Boulder CO 80305 Revised version submitted to International Journal of Chemical Kinetics, January 2010. Abstract The Cl-atom initiated oxidation of two esters, ethyl formate [HC(O)OCH 2CH 3] and ethyl acetate [CH 3C(O)OCH 2CH 3], has been studied near 1 atm. as a function of temperature (249 – 325 K) and O 2 partial pressure (50-700 Torr) using an environmental chamber technique. In both cases, Cl-atom attack at the CH 2 group is most important, leading in part to the formation of radicals of the type RC(O)OCH(O •)CH 3 [R=H, CH 3]. The atmospheric fate of these radicals involves competition between reaction with O 2 to produce an anhydride compound, RC(O)OC(O)CH 3, and the so-called α-ester rearrangement which produces an organic acid, RC(O)OH and an acetyl radical, CH 3C(O). For both species studied, the α-ester rearrangement is found to dominate in 1 atm. air at 298 K. Barriers to the rearrangement of 7.7±1.5 and 8.4±1.5 kcal/mole are estimated for CH 3C(O)OCH(O •)CH 3 and HC(O)OCH(O •)CH 3, respectively, leading to increased occurrence of the O 2 reaction at reduced temperature. The data are combined with those from similar studies of other simple esters to provide a correlation between the rate of occurrence of the α-ester rearrangement and the structure of the reacting radical.
    [Show full text]
  • The Chemistry of Salvia Divinorum
    The Chemistry of Salvia divinorum Thomas Anthony Munro Submitted in total fulfilment of the requirements of the degree of Doctor of Philosophy April 2006 Department of Chemistry The University of Melbourne 2 Abstract Salvia divinorum is a hallucinogenic sage used to treat illness by the Mazatec Indians of Mexico. Salvinorin A (1a), a neoclerodane diterpenoid isolated from the plant, is a potent, selective agonist at the κ opioid receptor (KOR), and is the first non-nitrogenous opioid. The plant is used recreationally as a hallucinogen, but is unpopular due to its dysphoric effects. 1a has been prohibited in Australia under an invalid systematic name. An early report of psychoactive alkaloids in S. divinorum proved to be irre- producible. Similarly, tests in mice suggesting the presence of psychoactive compounds other than 1a were confounded and therefore unreliable. O O O O 1 1 O O OR O R H H H H 2 H H O R 2 2 8 O O R O O O O O OR3 R1 R2 R1 R2 R3 1a 1d Ac OH 28a OH H H 1e H OAc 28b OH OH Me 1f H H 28c H OAc H In this work, an improved isolation method for 1a was developed, using fil- tration through activated carbon to decolourise the crude extract. Six new diterpenoids were isolated: salvinorins D–F (1d–1f) and divinatorins A–C (28a–28c). Five known terpenoids not previously reported from this species were also isolated. 3 4 The structure–activity relationships of 1a were evaluated via selective mod- ifications of each functional group.
    [Show full text]
  • United States Patent Office Patented May 3, 1966 1
    3,249,561 United States Patent Office Patented May 3, 1966 1. 2 fic temperature for forming the polyamide-acid of a speci FORMING A FoAME53,249,561 roi YIMEDE ARTICLE fied diamine and a specified dianhydride, several factors William Robert Hendrix, Buffalo, N.Y., assignor to E. must be considered. The maximum permissible tem du Pont de Nemours and Company, Wilmington, Del., perature will depend on the diamine used, the dianhydride a corporation of Delaware used, the particular solvent, the percentage of polyamide No Drawing. Fied Mar. 18, 1963, Ser. No. 266,065 acid desired and the minimum period of time that one 1. Claims. (CI. 260-2.5) desires for the reaction. For most combinations of dia mines and dianhydrides falling with the definitions given This invention relates to cellular structures of poly above, it is possible to form polymeric components of imides and a process for making them. O 100% polyamide-acid by conducting the reaction below In the prior art, resinous compositions have been made 100 C. However, temperatures up to 175° C. may be into foams by physically mixing the molten or plasticized tolerated to provide shapeable compositions. The partic resin with gases or blowing agents. However, obtaining ular temperature below 175 C. that must not be exceeded polyimide resins in the molten state is not easily possible for any particular combination of diamine, dianhydride, since the resins are resistant to heat and tend to degrade 5 Solvent and reaction time to provide a reaction product before or during melting. Using a plasticizer is also composed of sufficient polyamide-acid to be shapeable will difficult since the resins are quite resistant to most chemi Vary but can be determined by a simple test by any person cals.
    [Show full text]